Pancreatic mitochondrial complex I exhibits aberrant hyperactivity in diabetes

Jinzi Wu, Xiaoting Luo, Nopporn Thangthaeng, Nathalie Sumien, Zhenglan Chen, Margaret A. Rutledge, Siqun Jing, Michael J. Forster, Liang-Jun Yan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

It is well established that NADH/NAD+ redox balance is heavily perturbed in diabetes, and the NADH/NAD+ redox imbalance is a major source of oxidative stress in diabetic tissues. In mitochondria, complex I is the only site for NADH oxidation and NAD+ regeneration and is also a major site for production of mitochondrial reactive oxygen species (ROS). Yet how complex I responds to the NADH/NAD+ redox imbalance and any potential consequences of such response in diabetic pancreas have not been investigated. We report here that pancreatic mitochondrial complex I showed aberrant hyperactivity in either type 1 or type 2 diabetes. Further studies focusing on streptozotocin (STZ)-induced diabetes indicate that complex I hyperactivity could be attenuated by metformin. Moreover, complex I hyperactivity was accompanied by increased activities of complexes II to IV, but not complex V, suggesting that overflow of NADH via complex I in diabetes could be diverted to ROS production. Indeed in diabetic pancreas, ROS production and oxidative stress increased and mitochondrial ATP production decreased, which can be attributed to impaired pancreatic mitochondrial membrane potential that is responsible for increased cell death. Additionally, cellular defense systems such as glucose 6-phosphate dehydrogenase, sirtuin 3, and NQO1 were found to be compromised in diabetic pancreas. Our findings point to the direction that complex I aberrant hyperactivity in pancreas could be a major source of oxidative stress and β cell failure in diabetes. Therefore, inhibiting pancreatic complex I hyperactivity and attenuating its ROS production by various means in diabetes might serve as a promising approach for anti-diabetic therapies.

Original languageEnglish
Pages (from-to)119-129
Number of pages11
JournalBiochemistry and Biophysics Reports
Volume11
DOIs
StatePublished - 1 Sep 2017

Fingerprint

Medical problems
NAD
Oxidative stress
Pancreas
Reactive Oxygen Species
Oxidation-Reduction
Oxidative Stress
Sirtuin 3
Mitochondria
Experimental Diabetes Mellitus
Mitochondrial Membrane Potential
Glucosephosphate Dehydrogenase
Metformin
Cell death
Streptozocin
Type 2 Diabetes Mellitus
Regeneration
Cell Death
Adenosine Triphosphate
Tissue

Keywords

  • Complex I
  • Diabetes
  • Hyperactivity
  • Mitochondria
  • Pancreas
  • Redox imbalance
  • Streptozotocin

Cite this

Wu, Jinzi ; Luo, Xiaoting ; Thangthaeng, Nopporn ; Sumien, Nathalie ; Chen, Zhenglan ; Rutledge, Margaret A. ; Jing, Siqun ; Forster, Michael J. ; Yan, Liang-Jun. / Pancreatic mitochondrial complex I exhibits aberrant hyperactivity in diabetes. In: Biochemistry and Biophysics Reports. 2017 ; Vol. 11. pp. 119-129.
@article{678ac55669cc47fcb549c428f327b769,
title = "Pancreatic mitochondrial complex I exhibits aberrant hyperactivity in diabetes",
abstract = "It is well established that NADH/NAD+ redox balance is heavily perturbed in diabetes, and the NADH/NAD+ redox imbalance is a major source of oxidative stress in diabetic tissues. In mitochondria, complex I is the only site for NADH oxidation and NAD+ regeneration and is also a major site for production of mitochondrial reactive oxygen species (ROS). Yet how complex I responds to the NADH/NAD+ redox imbalance and any potential consequences of such response in diabetic pancreas have not been investigated. We report here that pancreatic mitochondrial complex I showed aberrant hyperactivity in either type 1 or type 2 diabetes. Further studies focusing on streptozotocin (STZ)-induced diabetes indicate that complex I hyperactivity could be attenuated by metformin. Moreover, complex I hyperactivity was accompanied by increased activities of complexes II to IV, but not complex V, suggesting that overflow of NADH via complex I in diabetes could be diverted to ROS production. Indeed in diabetic pancreas, ROS production and oxidative stress increased and mitochondrial ATP production decreased, which can be attributed to impaired pancreatic mitochondrial membrane potential that is responsible for increased cell death. Additionally, cellular defense systems such as glucose 6-phosphate dehydrogenase, sirtuin 3, and NQO1 were found to be compromised in diabetic pancreas. Our findings point to the direction that complex I aberrant hyperactivity in pancreas could be a major source of oxidative stress and β cell failure in diabetes. Therefore, inhibiting pancreatic complex I hyperactivity and attenuating its ROS production by various means in diabetes might serve as a promising approach for anti-diabetic therapies.",
keywords = "Complex I, Diabetes, Hyperactivity, Mitochondria, Pancreas, Redox imbalance, Streptozotocin",
author = "Jinzi Wu and Xiaoting Luo and Nopporn Thangthaeng and Nathalie Sumien and Zhenglan Chen and Rutledge, {Margaret A.} and Siqun Jing and Forster, {Michael J.} and Liang-Jun Yan",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.bbrep.2017.07.007",
language = "English",
volume = "11",
pages = "119--129",
journal = "Biochemistry and Biophysics Reports",
issn = "2405-5808",
publisher = "Elsevier BV",

}

Pancreatic mitochondrial complex I exhibits aberrant hyperactivity in diabetes. / Wu, Jinzi; Luo, Xiaoting; Thangthaeng, Nopporn; Sumien, Nathalie; Chen, Zhenglan; Rutledge, Margaret A.; Jing, Siqun; Forster, Michael J.; Yan, Liang-Jun.

In: Biochemistry and Biophysics Reports, Vol. 11, 01.09.2017, p. 119-129.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pancreatic mitochondrial complex I exhibits aberrant hyperactivity in diabetes

AU - Wu, Jinzi

AU - Luo, Xiaoting

AU - Thangthaeng, Nopporn

AU - Sumien, Nathalie

AU - Chen, Zhenglan

AU - Rutledge, Margaret A.

AU - Jing, Siqun

AU - Forster, Michael J.

AU - Yan, Liang-Jun

PY - 2017/9/1

Y1 - 2017/9/1

N2 - It is well established that NADH/NAD+ redox balance is heavily perturbed in diabetes, and the NADH/NAD+ redox imbalance is a major source of oxidative stress in diabetic tissues. In mitochondria, complex I is the only site for NADH oxidation and NAD+ regeneration and is also a major site for production of mitochondrial reactive oxygen species (ROS). Yet how complex I responds to the NADH/NAD+ redox imbalance and any potential consequences of such response in diabetic pancreas have not been investigated. We report here that pancreatic mitochondrial complex I showed aberrant hyperactivity in either type 1 or type 2 diabetes. Further studies focusing on streptozotocin (STZ)-induced diabetes indicate that complex I hyperactivity could be attenuated by metformin. Moreover, complex I hyperactivity was accompanied by increased activities of complexes II to IV, but not complex V, suggesting that overflow of NADH via complex I in diabetes could be diverted to ROS production. Indeed in diabetic pancreas, ROS production and oxidative stress increased and mitochondrial ATP production decreased, which can be attributed to impaired pancreatic mitochondrial membrane potential that is responsible for increased cell death. Additionally, cellular defense systems such as glucose 6-phosphate dehydrogenase, sirtuin 3, and NQO1 were found to be compromised in diabetic pancreas. Our findings point to the direction that complex I aberrant hyperactivity in pancreas could be a major source of oxidative stress and β cell failure in diabetes. Therefore, inhibiting pancreatic complex I hyperactivity and attenuating its ROS production by various means in diabetes might serve as a promising approach for anti-diabetic therapies.

AB - It is well established that NADH/NAD+ redox balance is heavily perturbed in diabetes, and the NADH/NAD+ redox imbalance is a major source of oxidative stress in diabetic tissues. In mitochondria, complex I is the only site for NADH oxidation and NAD+ regeneration and is also a major site for production of mitochondrial reactive oxygen species (ROS). Yet how complex I responds to the NADH/NAD+ redox imbalance and any potential consequences of such response in diabetic pancreas have not been investigated. We report here that pancreatic mitochondrial complex I showed aberrant hyperactivity in either type 1 or type 2 diabetes. Further studies focusing on streptozotocin (STZ)-induced diabetes indicate that complex I hyperactivity could be attenuated by metformin. Moreover, complex I hyperactivity was accompanied by increased activities of complexes II to IV, but not complex V, suggesting that overflow of NADH via complex I in diabetes could be diverted to ROS production. Indeed in diabetic pancreas, ROS production and oxidative stress increased and mitochondrial ATP production decreased, which can be attributed to impaired pancreatic mitochondrial membrane potential that is responsible for increased cell death. Additionally, cellular defense systems such as glucose 6-phosphate dehydrogenase, sirtuin 3, and NQO1 were found to be compromised in diabetic pancreas. Our findings point to the direction that complex I aberrant hyperactivity in pancreas could be a major source of oxidative stress and β cell failure in diabetes. Therefore, inhibiting pancreatic complex I hyperactivity and attenuating its ROS production by various means in diabetes might serve as a promising approach for anti-diabetic therapies.

KW - Complex I

KW - Diabetes

KW - Hyperactivity

KW - Mitochondria

KW - Pancreas

KW - Redox imbalance

KW - Streptozotocin

UR - http://www.scopus.com/inward/record.url?scp=85024836942&partnerID=8YFLogxK

U2 - 10.1016/j.bbrep.2017.07.007

DO - 10.1016/j.bbrep.2017.07.007

M3 - Article

AN - SCOPUS:85024836942

VL - 11

SP - 119

EP - 129

JO - Biochemistry and Biophysics Reports

JF - Biochemistry and Biophysics Reports

SN - 2405-5808

ER -